VISIPAQUE

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Japan, Lithuania, Malta, New Zealand, Poland, Romania, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug VISIPAQUE contains one active pharmaceutical ingredient (API):

1
UNII HW8W27HTXX - IODIXANOL
 
Read more about Iodixanol

Medication package inserts

Below package inserts are available for further reading:

Document Type Information Source  
 VISIPAQUE Solution for injection MPI, EU: SmPC Medicines and Medical Devices Safety Authority (NZ)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
V08AB09 Iodixanol V Various → V08 Contrast media → V08A X-ray contrast media, iodinated → V08AB Watersoluble, nephrotropic, low osmolar X-ray contrast media
Discover more medicines within V08AB09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
BR Câmara de Regulação do Mercado de Medicamentos 541612090001004, 541612090001114, 541612090001204, 541612090001704, 541612090001804, 541616070002203
CA Health Products and Food Branch 02145766, 02145774
EC Agencia Nacional de Regulación, Control y Vigilancia Sanitaria 5005-MEE-0320
EE Ravimiamet 1038114, 1038125, 1079344, 1079355, 1079366, 1079377, 1079388, 1079399, 1140905, 1140927, 1140972, 1140983, 1141029, 1141030, 1141074, 1141108, 1141153, 1141164, 1141175, 1141186
ES Centro de información online de medicamentos de la AEMPS 60636, 60637
FI Lääkealan turvallisuus- ja kehittämiskeskus 019121, 019132, 582882, 583401, 583450, 583518, 583609, 583708
FR Base de données publique des médicaments 60567418, 60960777
GB Medicines & Healthcare Products Regulatory Agency 377352, 398066, 398067, 80822, 80823, 80824, 80825, 80828
HK Department of Health Drug Office 43490, 43491
HR Agencija za lijekove i medicinske proizvode HR-H-289648429, HR-H-385628224
JP 医薬品医療機器総合機構 7219420A1031, 7219420A2038, 7219420A3034, 7219420A4030, 7219420A5037
LT Valstybinė vaistų kontrolės tarnyba 1010525, 1010526, 1010527, 1010528, 1011301, 1011302, 1011303, 1011304, 1021975, 1021976, 1021977, 1021979, 1021980, 1021981, 1026459, 1026460, 1069917, 1069918, 1069919, 1069920, 1078673, 1078674, 1078675, 1078676, 1078677, 1089024, 1089025, 1089026, 1089027
MT Medicines Authority MA023/00201, MA023/00202
NZ Medicines and Medical Devices Safety Authority 7154, 7159
PL Rejestru Produktów Leczniczych 100093688, 100195147
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W12012001, W12012002, W12012003, W12012004, W12012005, W12012007, W12012008, W12013001, W12013002, W12013003, W12013004, W12013005, W12013006, W12013007
SG Health Sciences Authority 08882P, 08883P
TN Direction de la Pharmacie et du Médicament 2453041, 2453042, 2453043
TR İlaç ve Tıbbi Cihaz Kurumu 8699688772143, 8699688772150, 8699688772242, 8699688772259, 8699688772266
US FDA, National Drug Code 0407-2222, 0407-2223
ZA Health Products Regulatory Authority 31/28/0171, 31/28/0172, 31/28/0175, 31/28/0176, 31/28/0177, 36/28/0134, 36/28/0136

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.